GRÜNENTHAL TAKES FULL OWNERSHIP OF GRÜNENTHAL MEDS, THE JOINT VENTURE ESTABLISHED WITH KYOWA KIRIN FOR ITS ESTABLISHED MEDICINES BRANDS

Contributed by: News Aktuell

Issued by news aktuell/OTS on behalf of Grünenthal Group

Logo

Tags

Leveraged buyout

Medicine

More Like This

MAREN THUROW STARTS AS NEW HEAD GLOBAL COMMUNICATIONS AT GRÜNENTHAL

GRÜNENTHAL ANNOUNCES ACQUISITION OF THE RIGHTS TO CIALIS® FROM LILLY IN MEXICO, BRAZIL & COLOMBIA

Valinor Pharma Announces Acquisition by Grünenthal with a Total Deal Value of Approximately $250 Million

GRÜNENTHAL LICENSES EXCLUSIVE SOUTH KOREAN RIGHTS TO QUTENZA® TO BCWORLD PHARM

GRÜNENTHAL PRO IS JOINING SHL MEDICAL'S ALLIANCE PARTNERSHIP NETWORK TO OFFER FINAL ASSEMBLY SERVICE FOR MOLLY® AUTOINJECTORS

GRÜNENTHAL'S PROPRIETARY NAV 1.8 INHIBITOR ENTERS CLINICAL DEVELOPMENT

Kyowa Kirin International and NewBridge Pharmaceuticals Enter Into Agreement to Improve Access to Medicines for Rare Disease Patients Across Middle East and North Africa

Kyowa Kirin Successfully Completes Acquisition of Orchard Therapeutics, a Global Gene Therapy Leader for Rare Diseases